Biogen acquires sole rights to MS drug from Elan for $3.25B

02/7/2013 | Reuters · Genetic Engineering & Biotechnology News

Biogen Idec agreed to pay Elan $3.25 billion plus future royalties to acquire all rights to multiple sclerosis drug Tysabri, or natalizumab. Tysabri was jointly developed by Biogen and Elan. The deal will strengthen Biogen's presence in the multiple sclerosis drug market as it awaits the FDA's decision on another MS drug, Tecfidera, or dimethyl fumarate.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC